CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 404 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR A Cancer Revolution comes to Manchester: Patrick’s review November 24, 2021 Effects of Patient Navigation, Lower-Cost Drug Alternatives on the Cost of... September 26, 2022 FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial... November 22, 2022 Promising Cancer Drug Combines Chemo And Light Therapy Into One Powerful... May 5, 2020 Load more HOT NEWS Adding 24 Months of ADT Improves Metastasis-Free Survival in Patients with... Rise in Brain Metastases Detected in Patients with Stage IV NSCLC... Genetic Testing for Bladder Cancer: What People With Cancer and Their... Blind Customer Surprised With Sweet Message In Braille For Her Birthday
